Zacks Research Issues Positive Outlook for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at Zacks Research increased their Q1 2026 earnings per share estimates for Corcept Therapeutics in a research note issued on Monday, January 27th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings per share of $0.46 for the quarter, up from their previous estimate of $0.45. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2026 earnings at $0.56 EPS, Q3 2026 earnings at $0.74 EPS, Q4 2026 earnings at $0.74 EPS and FY2026 earnings at $2.50 EPS.

Several other equities research analysts have also issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Finally, StockNews.com cut Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $65.25.

Corcept Therapeutics Stock Up 0.6 %

CORT stock opened at $60.66 on Wednesday. Corcept Therapeutics has a one year low of $20.84 and a one year high of $62.98. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The firm’s fifty day moving average is $55.45 and its 200 day moving average is $46.40. The firm has a market cap of $6.36 billion, a PE ratio of 48.14 and a beta of 0.56.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The firm had revenue of $182.55 million during the quarter, compared to analyst estimates of $171.97 million. During the same period in the previous year, the firm earned $0.28 EPS. The business’s quarterly revenue was up 47.7% on a year-over-year basis.

Institutional Investors Weigh In On Corcept Therapeutics

Large investors have recently modified their holdings of the business. Capital Performance Advisors LLP purchased a new position in shares of Corcept Therapeutics in the third quarter worth about $25,000. Kathleen S. Wright Associates Inc. acquired a new stake in Corcept Therapeutics in the 3rd quarter valued at about $36,000. USA Financial Formulas purchased a new position in Corcept Therapeutics in the 4th quarter worth approximately $54,000. Newbridge Financial Services Group Inc. acquired a new position in shares of Corcept Therapeutics during the 4th quarter worth approximately $58,000. Finally, GAMMA Investing LLC grew its position in shares of Corcept Therapeutics by 85.4% in the third quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 1,147 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insider Activity at Corcept Therapeutics

In related news, insider Joseph Douglas Lyon sold 1,411 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $56.72, for a total transaction of $80,031.92. Following the completion of the sale, the insider now directly owns 8,494 shares in the company, valued at approximately $481,779.68. The trade was a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Guyer sold 6,606 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $48.97, for a total value of $323,495.82. Following the completion of the transaction, the insider now owns 5,796 shares in the company, valued at $283,830.12. The trade was a 53.27 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,011 shares of company stock valued at $1,951,268. 20.50% of the stock is owned by corporate insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.